Tirzepatide 30 mg

Research Material

Tirzepatide 30 mg

$50.00

In stock

Research identity: dual GIP/GLP-1 receptor agonist with a large human clinical literature.

  • Phase 3 evidence snapshot
  • FDA-regulated product context kept separate from catalog identity
  • Mechanism map, evidence limits, and primary sources below

Catalog scope: 30 mg distinguishes this inventory listing; it is not a dose, schedule, or use instruction. This catalog material is not an FDA-approved drug product. For laboratory research only; not for human or veterinary use.

COMPOUND DOSSIER Read identity, mechanism, evidence, limits, and sources
Catalog sourceResearch Here
Request methodEmail review
Research recordFull dossier below

BUILD ONE COMPLETE LIST

Need more than one item?

Add this item, keep browsing, and add every product or option you need. Your list stays saved in this browser until you send one complete email request or remove it.

  1. 1Choose an in-stock or available-for-request option and quantity.
  2. 2Add it to your request list and continue shopping.
  3. 3Review the full list and send one email request.

RESEARCH HERE · COMPOUND DOSSIER

The record behind the shelf.

Plain-language identity, mechanism, evidence maturity, study endpoints, limitations, and direct source records—organized for careful reading, never copied from a dosing site.

PHASE 3 HUMAN EVIDENCEREGULATED DRUG CONTEXT EXISTS

DUAL-RECEPTOR LIGAND

Tirzepatide

A 39-amino-acid, lipidated peptide agonist at GIP and GLP-1 receptors. It has a large clinical literature and appears in specific FDA-approved drug products—but those approvals do not transfer to unrelated catalog material.

GIPRGLP-1R
Compound class
Dual incretin-receptor agonist
Strongest indexed evidence
Randomized phase 3 human studies
Regulatory context
Approved active ingredient in specific FDA-reviewed products
Catalog distinction
This listing is not an FDA-approved drug product

01

What it is

Tirzepatide activates GIP and GLP-1 receptors. PubChem describes a linear 39-amino-acid peptide conjugated to a C20 fatty diacid moiety through a linker.

Identity rule: a shared ingredient name does not make a catalog vial interchangeable with an FDA-reviewed formulation.

02

What researchers measured

  • Body-weight endpoints in randomized controlled trials
  • Glycemic and cardiometabolic measures
  • Adverse events, discontinuations, and tolerability
  • Outcomes tied to prespecified populations and regulated formulations

03

What the record does not prove

  • That this catalog material matches an approved formulation
  • That a strength label is a clinical dosing instruction
  • That a COA substitutes for FDA manufacturing review
  • That trial outcomes apply outside the studied population and protocol

EVIDENCE SNAPSHOT

Separate clinical evidence from catalog identity.

The records below are valuable precisely because their products, methods, populations, and oversight are defined.

2022 · PHASE 3SURMOUNT-1 randomized controlled trial

2,539 adults; 72-week body-weight and cardiometabolic endpoints in a defined trial.

PMID 35658024 ↗ 2026 · FDA LABELZepbound prescribing information

Current regulated-product context, including indications, boxed warning, contraindications, and manufacturing-specific presentation.

FDA LABEL ↗ IDENTITY DATABASEPubChem compound record

Chemical identity, synonyms, structure, molecular formula, and linked literature.

PUBCHEM ↗

DETAILED COMPOUND GUIDE

Benefits, risks, interactions, and the regulated record.

Tirzepatide has an FDA-reviewed product label and extensive human evidence. This guide keeps that legitimate drug information separate from an unrelated catalog vial.

01Reported clinical findings+

In SURMOUNT-1, 2,539 adults without diabetes were followed for 72 weeks. Mean body-weight change was −15.0%, −19.5%, and −20.9% in the three tirzepatide groups, compared with −3.1% for placebo. The study also measured categorical weight loss and prespecified cardiometabolic outcomes.

Tirzepatide is the active ingredient in specific FDA-approved products. Approval covers those manufacturers, formulations, controls, labels, and presentations—not every vial bearing the molecule name.

02How it works+

Tirzepatide is a dual GIP- and GLP-1-receptor agonist. In regulated clinical use, the combined incretin signaling is associated with glucose-dependent insulin effects, appetite and food-intake changes, and delayed gastric emptying.

The PubChem identity record describes a 39-amino-acid linear peptide with a lipid moiety that extends pharmacokinetic exposure.

03Common and serious adverse effects+

The current FDA label lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, and decreased appetite among common adverse reactions.

Label warnings address thyroid C-cell tumors observed in rats, acute pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity, diabetic-retinopathy complications in people with type 2 diabetes, and aspiration risk during anesthesia or deep sedation.

04Contraindications+

For the FDA-approved Zepbound product, contraindications include a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to tirzepatide or product excipients.

This is regulated-product information. It does not validate or authorize this catalog material for clinical use.

05Interactions and special cautions+
  • Delayed gastric emptying may affect absorption of oral medicines.
  • Using insulin or insulin secretagogues can increase hypoglycemia risk.
  • The FDA label warns that oral hormonal contraceptive effectiveness may be reduced after initiation and dose escalation.
  • Pregnancy, planned procedures requiring anesthesia, severe gastrointestinal disease, and changes in vision are label-directed clinical review topics.

No controlled evidence validates the multi-peptide “stacking suggestions” published by commercial guide sites.

06Protocol, storage, and claim audit+

The FDA prescribing information contains the authorized dosing, administration, supplied concentrations, storage conditions, warnings, and medication guide for the approved product. Those directions cannot be transferred to an unapproved third-party vial.

SUPPORTEDDual-receptor pharmacology and large randomized human evidence

REGULATED CONTEXTSpecific FDA-approved tirzepatide drug products

NOT TRANSFERABLEApproved-product dosing, storage, or safety assumptions applied to this catalog material

NOT VALIDATEDCommercial stacking schedules and third-party unit charts

REFERENCE DESK

The complete guide, with label-level corrections.

Commercial pages mix accurate drug-label information with unverified peptide interactions and stacking advice. This version keeps both visible while identifying which is which.

BENEFITS & EFFECTS INDEX

What human studies support

SUPPORTEDBody-weight reduction, glycemic control, appetite/food-intake effects, and multiple cardiometabolic outcomes in defined clinical populations

FDA CONTEXTSpecific approved indications for specific Zepbound and Mounjaro drug products

NOT A VIAL CLAIMEquivalent efficacy, purity, safety, absorption, or formulation performance for this catalog material

ADVERSE-EFFECT INDEX

Common and serious topics

Common label-listed reactions: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, decreased appetite, fatigue, injection-site reactions, belching, and hair loss.

Warning-level topics: thyroid C-cell tumors in rats, pancreatitis, gallbladder disease, hypoglycemia with certain medicines, kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity, diabetic-retinopathy complications, and aspiration under anesthesia or deep sedation.

INTERACTION INDEX

Label-supported versus commercial

  • FDA label: insulin/insulin secretagogues, oral medicines affected by delayed gastric emptying, and oral hormonal contraceptives.
  • Clinical caution: dehydration-promoting medicines and planned anesthesia require individualized review.
  • Commercial guides additionally name: alcohol, metformin, berberine, chromium, stimulants, appetite suppressants, growth-hormone analogs, other GLP agents, tesamorelin, IGF-1 products, GHRP-2/6, hexarelin, BAM-15, LL-37, and oxytocin.

The long commercial list is not the same as a validated interaction study or an FDA contraindication.

CONTRAINDICATIONS & SPECIAL POPULATIONS

Use the exact regulatory categories

Formal FDA contraindications for approved Zepbound: personal/family history of medullary thyroid carcinoma, MEN 2, or serious hypersensitivity to tirzepatide/excipients.

Pregnancy, breastfeeding, severe gastrointestinal disease, type 1 diabetes, diabetic retinopathy, and peri-anesthesia risks require separate label-guided clinical consideration; they should not all be mislabeled as formal contraindications.

STACKING CLAIMS INDEX

Named on public guide pages

AOD-9604TesamorelinSemaxSelankNAD+MOTS-CBPC-157CJC / Ipamorelin

Claims include additional fat loss, visceral-fat support, mood, energy, gastrointestinal comfort, muscle preservation, and recovery. Controlled evidence for these combinations with tirzepatide was not established by the cited pages.

STORAGE & HANDLING

Approved product versus catalog vial

The FDA label defines storage and handling for the approved presentation. A generic lyophilized-peptide chart or an approved pen/vial label cannot validate storage of this catalog material.

Require material-specific stability, temperature, light, solvent, concentration, sterility, endotoxin, and beyond-use documentation.

Is tirzepatide FDA approved?+

The active ingredient is approved in specific FDA-reviewed drug products. This catalog listing is not one of those approved products.

What are the most common side effects?+

Gastrointestinal reactions predominate in the regulated clinical record, including nausea, diarrhea, vomiting, constipation, indigestion, and abdominal pain.

Why can oral medicines be affected?+

Tirzepatide delays gastric emptying, which may change absorption of oral medicines. The FDA label gives specific contraceptive guidance for approved treatment.

Can an FDA dose chart be used for a research vial?+

No. The approved directions assume a verified formulation, concentration, presentation, manufacturing system, and clinical oversight.

REFERENCE LAYERPrimary and authoritative sources shown above control the evidence classification. Reported-practice notes are retained without public vendor attribution.
FORMULATION CHECK

Approved product or catalog material?

FDA approval applies to a particular sponsor, formulation, manufacturing controls, label, and presentation—not every material sold under the same molecule name.

QUALITY CHECK

What belongs in the batch record?

Lot-linked identity, purity method, mass or fill verification, and—when relevant—sterility and endotoxin records should be evaluated separately.

STRENGTH CHECK

20, 30, or 40 mg

The number on this listing distinguishes catalog inventory. It is not a dose, schedule, protocol, or comparison to an FDA-approved presentation.

SOURCE SHELF

Open the original records.